CD39+常规CD4+ T细胞具有耗竭特性和细胞毒性潜能,在CTLA-4阻断后浸润肿瘤并扩张

IF 7.2 2区 医学 Oncoimmunology Pub Date : 2023-08-18 eCollection Date: 2023-01-01 DOI:10.1080/2162402X.2023.2246319
Sabrina N Bossio, Carolina Abrate, Jimena Tosello Boari, Constanza Rodriguez, Fernando P Canale, María C Ramello, Valentina Brunotto, Wilfrid Richer, Dario Rocha, Christine Sedlik, Anne Vincent-Salomon, Edith Borcoman, Andres Del Castillo, Adriana Gruppi, Elmer Fernandez, Eva V Acosta Rodríguez, Eliane Piaggio, Carolina L Montes
{"title":"CD39+常规CD4+ T细胞具有耗竭特性和细胞毒性潜能,在CTLA-4阻断后浸润肿瘤并扩张","authors":"Sabrina N Bossio, Carolina Abrate, Jimena Tosello Boari, Constanza Rodriguez, Fernando P Canale, María C Ramello, Valentina Brunotto, Wilfrid Richer, Dario Rocha, Christine Sedlik, Anne Vincent-Salomon, Edith Borcoman, Andres Del Castillo, Adriana Gruppi, Elmer Fernandez, Eva V Acosta Rodríguez, Eliane Piaggio, Carolina L Montes","doi":"10.1080/2162402X.2023.2246319","DOIUrl":null,"url":null,"abstract":"<p><p>Conventional CD4<sup>+</sup> T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Here, we describe a subset of tumor-infiltrating Tconv cells characterized by the expression of CD39. In several mouse cancer models, we observed that CD39<sup>+</sup> Tconv cells accumulated in tumors but were absent in lymphoid organs. Compared to tumor CD39<sup>-</sup> counterparts, CD39<sup>+</sup> Tconv cells exhibited a cytotoxic and exhausted signature at the transcriptomic level, confirmed by high protein expression of inhibitory receptors and transcription factors related to the exhaustion. Additionally, CD39<sup>+</sup> Tconv cells showed increased production of IFN<math><mi>γ</mi></math>, granzyme B, perforin and CD107a expression, but reduced production of TNF. Around 55% of OVA-specific Tconv from B16-OVA tumor-bearing mice, expressed CD39. <i>In vivo</i> CTLA-4 blockade induced the expansion of tumor CD39<sup>+</sup> Tconv cells, which maintained their cytotoxic and exhausted features. In breast cancer patients, CD39<sup>+</sup> Tconv cells were found in tumors and in metastatic lymph nodes but were less frequent in adjacent non-tumoral mammary tissue and not detected in non-metastatic lymph nodes and blood. Human tumor CD39<sup>+</sup> Tconv cells constituted a heterogeneous cell population with features of exhaustion, high expression of inhibitory receptors and CD107a. We found that high CD4 and ENTPD1 (CD39) gene expression in human tumor tissues correlated with a higher overall survival rate in breast cancer patients. Our results identify CD39 as a biomarker of Tconv cells, with characteristics of both exhaustion and cytotoxic potential, and indicate CD39<sup>+</sup> Tconv cells as players within the immune response against tumors.</p>","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":null,"pages":null},"PeriodicalIF":7.2000,"publicationDate":"2023-08-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599196/pdf/","citationCount":"0","resultStr":"{\"title\":\"CD39<sup>+</sup> conventional CD4<sup>+</sup> T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade.\",\"authors\":\"Sabrina N Bossio, Carolina Abrate, Jimena Tosello Boari, Constanza Rodriguez, Fernando P Canale, María C Ramello, Valentina Brunotto, Wilfrid Richer, Dario Rocha, Christine Sedlik, Anne Vincent-Salomon, Edith Borcoman, Andres Del Castillo, Adriana Gruppi, Elmer Fernandez, Eva V Acosta Rodríguez, Eliane Piaggio, Carolina L Montes\",\"doi\":\"10.1080/2162402X.2023.2246319\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Conventional CD4<sup>+</sup> T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Here, we describe a subset of tumor-infiltrating Tconv cells characterized by the expression of CD39. In several mouse cancer models, we observed that CD39<sup>+</sup> Tconv cells accumulated in tumors but were absent in lymphoid organs. Compared to tumor CD39<sup>-</sup> counterparts, CD39<sup>+</sup> Tconv cells exhibited a cytotoxic and exhausted signature at the transcriptomic level, confirmed by high protein expression of inhibitory receptors and transcription factors related to the exhaustion. Additionally, CD39<sup>+</sup> Tconv cells showed increased production of IFN<math><mi>γ</mi></math>, granzyme B, perforin and CD107a expression, but reduced production of TNF. Around 55% of OVA-specific Tconv from B16-OVA tumor-bearing mice, expressed CD39. <i>In vivo</i> CTLA-4 blockade induced the expansion of tumor CD39<sup>+</sup> Tconv cells, which maintained their cytotoxic and exhausted features. In breast cancer patients, CD39<sup>+</sup> Tconv cells were found in tumors and in metastatic lymph nodes but were less frequent in adjacent non-tumoral mammary tissue and not detected in non-metastatic lymph nodes and blood. Human tumor CD39<sup>+</sup> Tconv cells constituted a heterogeneous cell population with features of exhaustion, high expression of inhibitory receptors and CD107a. We found that high CD4 and ENTPD1 (CD39) gene expression in human tumor tissues correlated with a higher overall survival rate in breast cancer patients. Our results identify CD39 as a biomarker of Tconv cells, with characteristics of both exhaustion and cytotoxic potential, and indicate CD39<sup>+</sup> Tconv cells as players within the immune response against tumors.</p>\",\"PeriodicalId\":19683,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2023-08-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10599196/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402X.2023.2246319\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402X.2023.2246319","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

传统的 CD4+ T(Tconv)淋巴细胞在肿瘤免疫中发挥着重要作用;然而,人们对它们在消除肿瘤方面的贡献仍然知之甚少。在这里,我们描述了以表达 CD39 为特征的肿瘤浸润 Tconv 细胞亚群。在几种小鼠癌症模型中,我们观察到 CD39+ Tconv 细胞在肿瘤中聚集,但在淋巴器官中却不存在。与肿瘤CD39-对应细胞相比,CD39+ Tconv细胞在转录组水平上表现出细胞毒性和衰竭特征,与衰竭相关的抑制受体和转录因子的高蛋白表达证实了这一点。此外,CD39+ Tconv 细胞的 IFNγ、颗粒酶 B、穿孔素和 CD107a 表达量增加,但 TNF 的产生量减少。来自 B16-OVA 肿瘤小鼠的约 55% 的 OVA 特异性 Tconv 表达 CD39。体内 CTLA-4 阻断诱导了肿瘤 CD39+ Tconv 细胞的扩增,这些细胞保持了细胞毒性和衰竭特征。在乳腺癌患者的肿瘤和转移淋巴结中发现了 CD39+ Tconv 细胞,但在邻近的非肿瘤乳腺组织中较少发现,在非转移淋巴结和血液中也未检测到。人类肿瘤 CD39+ Tconv 细胞构成了一个异质性细胞群,具有衰竭、高表达抑制性受体和 CD107a 的特征。我们发现,人类肿瘤组织中 CD4 和 ENTPD1(CD39)基因的高表达与乳腺癌患者较高的总生存率相关。我们的研究结果确定了 CD39 是 Tconv 细胞的生物标志物,具有衰竭和细胞毒性潜能的特征,并表明 CD39+ Tconv 细胞是抗肿瘤免疫反应的参与者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
CD39+ conventional CD4+ T cells with exhaustion traits and cytotoxic potential infiltrate tumors and expand upon CTLA-4 blockade.

Conventional CD4+ T (Tconv) lymphocytes play important roles in tumor immunity; however, their contribution to tumor elimination remains poorly understood. Here, we describe a subset of tumor-infiltrating Tconv cells characterized by the expression of CD39. In several mouse cancer models, we observed that CD39+ Tconv cells accumulated in tumors but were absent in lymphoid organs. Compared to tumor CD39- counterparts, CD39+ Tconv cells exhibited a cytotoxic and exhausted signature at the transcriptomic level, confirmed by high protein expression of inhibitory receptors and transcription factors related to the exhaustion. Additionally, CD39+ Tconv cells showed increased production of IFNγ, granzyme B, perforin and CD107a expression, but reduced production of TNF. Around 55% of OVA-specific Tconv from B16-OVA tumor-bearing mice, expressed CD39. In vivo CTLA-4 blockade induced the expansion of tumor CD39+ Tconv cells, which maintained their cytotoxic and exhausted features. In breast cancer patients, CD39+ Tconv cells were found in tumors and in metastatic lymph nodes but were less frequent in adjacent non-tumoral mammary tissue and not detected in non-metastatic lymph nodes and blood. Human tumor CD39+ Tconv cells constituted a heterogeneous cell population with features of exhaustion, high expression of inhibitory receptors and CD107a. We found that high CD4 and ENTPD1 (CD39) gene expression in human tumor tissues correlated with a higher overall survival rate in breast cancer patients. Our results identify CD39 as a biomarker of Tconv cells, with characteristics of both exhaustion and cytotoxic potential, and indicate CD39+ Tconv cells as players within the immune response against tumors.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Oncoimmunology
Oncoimmunology ONCOLOGY-IMMUNOLOGY
CiteScore
12.80
自引率
2.80%
发文量
276
期刊介绍: Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy. While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.
期刊最新文献
Multiprong CD38 targeting to enhance anti-PD1 immune checkpoint blockade efficacy. Multiplex spatial analysis reveals increased CD137 expression and m-MDSC neighboring tumor cells in refractory classical Hodgkin Lymphoma Transcriptomics-based characterization of the immuno-stromal microenvironment in pediatric low-grade glioma Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment Peripheral CX3CR1+ T cells combined with PD-1 blockade therapy potentiates the anti-tumor efficacy for lung cancer
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1